Topics
Gliomas | Treatment | Clinical trials | Pamiparib
Home > Publications > Topics > Gliomas > Treatment > Clinical trials > Pamiparib
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J,
Burt Nabors L, Ozer BH, Desai A, Omuro A, Desideri S, Danda N,
Grossman S, Bindra RS.
Phase I/II and
Window-of-Opportunity Study of Pamiparib and Metronomic
Temozolomide for Recurrent IDH Mutant Gliomas.
Neuro
Oncol. 2025 Oct 16:noaf246. doi:
10.1093/neuonc/noaf246. PMID:
41099363. Interventional study˰
ˍ
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J,
Burt Nabors L, Ozer BH, Desai A, Omuro A, Desideri S, Danda N,
Grossman S, Bindra RS.
Phase I/II and
Window-of-Opportunity Study of Pamiparib and Metronomic
Temozolomide for Recurrent IDH Mutant Gliomas.
Neuro
Oncol. 2025 Oct 16:noaf246. doi:
10.1093/neuonc/noaf246. PMID:
41099363. Interventional study˰
ˍ
Ellingson BM, Cloughesy TF, Ye X, Teraishi A, Raymond C, Oshima S,
Sanvito F, Wen PY, Walbert T, Campian JL, Nabors LB, Ozer BH,
Desai A, Omuro A, Desideri S, Danda N, Grossman SA, Bindra RS,
Schiff D.
Tumor Growth Rate (TGR)
Analysis Predicts Survival in a Multicenter Phase II Study of the
PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent
IDH-Mutant Gliomas (ABTC-1801).
AJNR
Am J Neuroradiol. 2026 May 29:ajnr.A9438. doi:
10.3174/ajnr.A9438. PMID:
42217836. Trial
registrationID: NCT03914742˰
ˍ